A Study of Orally Administered Pimodivir in Adult Participants With Renal Impairment

Inclusion Criteria: * Participant must have a body mass index (Body Mass Index \[BMI\]; body weight (Kilograms per height\^2 \[kg/m\^2\]) between 18.0 and 38.0 kg/m\^2, inclusive, and body weight not less than 50 kg, inclusive, at screening * Participants with normal renal function must have normal values for alanine aminotransferase (ALT) and aspartate aminotransferase (AST) (less than or equal to \[\<=\]1.5\*upper limit of laboratory normal range \[ULN\]) at screening and Day -1 and participants with renal impairment and end-stage renal disease (ESRD) must have values for ALT and AST \<=3.0\*ULN at screening and Day -1 * Participants with normal renal function must have glomerular filtration rate (GFR) greater than or equal to (\>=) 90 milliliters per minute (mL/min) and participants with renal impairment (mild, moderate and severe) and ESRD must have \>=60 mL/min to \<90 mL/min (for Mild renal impairment); \>=30 to \<60 mL/min (for Moderate renal impairment); \>=15 mL/min to \<30 mL/min (for Severe renal impairment not on dialysis); and \<15 mL/min (for ESRD not on dialysis) * Participants with normal renal function must have a systolic blood pressure (after the participant is supine for 5 minutes) between 90 millimeters of mercury (mmHg), extremes included, and diastolic blood pressure no higher than 90 mmHg and participants with renal impairment (mild, moderate and severe) and ESRD must have a systolic blood pressure (after the participant is supine for 5 minutes) between 90 and 159 mmHg, extremes included, and diastolic blood pressure no higher than 99 mmHg. If blood pressure is out of range, 1 repeated assessment is permitted after an additional 5 minutes of rest * A woman, except if postmenopausal, must have a negative highly sensitive serum pregnancy test (beta human chorionic gonadotropin \[beta hCG\]) at screening and a negative urine pregnancy test on Day -1 Exclusion Criteria: * Participant has any surgical or medical condition that potentially may alter the absorption, metabolism, or excretion of the study drug (for example \[e.g.\], Crohn's disease), with the exception of renal impairment * Participant has a history of hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV) antibody or any other clinically active liver disease at screening * Participant has a history of clinically significant drug allergy such as, but not limited to, sulfonamides and penicillin, or drug allergy diagnosed in previous studies with experimental drugs * Participant has known allergies, hypersensitivity, or intolerance to pimodivir or its excipients * Participant has evidence of an active infection